Biorest Liposomal Alendronate With Stenting sTudy (BLAST)

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lesiontargetleftlesionsgraft
  Phrases that lowered it: subjectindexsubjectshistorysafety
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Collaborators: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 11.7% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Maximum age: 80 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 4201 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK) NCT01510327 · started 2009 · scored riskier than 82% of active trials completed
• The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL) NCT01500434 · started 2009 · scored riskier than 83% of active trials completed
• The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions NCT00823212 · started 2009 · scored riskier than 82% of active trials completed
• Vascular Effects of Alirocumab in Acute MI-Patients NCT03067844 · started 2017 · scored riskier than 72% of active trials completed
• Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy NCT00944333 · started 2009 · scored riskier than 69% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.